新型声动力治疗设备开发商Alpheus Medical筹集了5200万美元B轮融资，以推进突破性的胶质母细胞瘤治疗-动脉网

Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy

CISION 等信源发布 2025-05-15 20:58



可切换为仅中文







Funding will support a randomized Phase

资金将支持随机化的阶段

study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma

新型声动力疗法在初诊胶质母细胞瘤患者中的研究

CHANHASSEN, Minn.

明尼苏达州查纳森

，

May 15, 2025

2025年5月15日

/PRNewswire/ --

Alpheus Medical, Inc

阿尔菲斯医疗公司

., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the closing of an oversubscribed

一家私人临床阶段的肿瘤学公司，开创了用于治疗实体瘤癌症的声动力疗法（SDT），今天宣布了一项超额认购的结束。

$52 million

5200万美元

Series B financing round. The funds will support a Phase

B轮融资。这笔资金将支持一个阶段

randomized controlled trial (RCT) evaluating the efficacy of SDT in patients with newly diagnosed glioblastoma (GBM) – one of the most aggressive and deadly forms of brain cancer.

随机对照试验（RCT）评估SDT在新诊断的胶质母细胞瘤（GBM）患者中的疗效——GBM是最具侵袭性和致命性的脑癌类型之一。

继续阅读

Backed by leading healthcare investors, the round was co-led by

由领先的医疗保健投资者支持，本轮融资由

HealthQuest Capital

健康探索资本

and

和

Samsara BioCapital

Samsara生物资本

with participation from existing investors

现有投资者参与其中

OrbiMed

奥博资本

and

和

Action Potential Venture Capital

动作电位风险投资公司

. In addition, venture investors committed to transforming cancer care participated, including

此外，致力于转变癌症护理的风险投资者也参与其中，包括

BrightEdge

, the impact investment and innovation arm of the American Cancer Society, the

，美国癌症协会的影响投资和创新部门，

Brain Tumor Investment Fund

脑肿瘤投资基金

, a subsidiary of the National Brain Tumor Society, and

，是国家脑肿瘤协会的子公司，和

Sontag Innovation Fund

桑塔格创新基金

, a subsidiary of The Sontag Foundation.

，是桑塔格基金会的子公司。

'This investment is a key inflection point for Alpheus and the glioblastoma community – advancing sonodynamic therapy from promise to clinical validation.'

“这项投资是阿尔菲厄斯和胶质母细胞瘤社区的关键转折点——推动声动力疗法从希望走向临床验证。”

Post this

发布这个

'The complex and diffuse nature of glioblastomas has long hindered therapeutic innovation,' said

“胶质母细胞瘤的复杂性和弥漫性长期以来一直阻碍着治疗创新，”

Conrad Wang M.D

康拉德·王医学博士

., Partner at HealthQuest Capital. 'Alpheus' sonodynamic therapy represents a novel, non-invasive whole brain approach with compelling early data. This investment reflects our commitment to advancing transformative technologies that seek to fill critical gaps in patient unmet needs.'

HealthQuest Capital的合伙人表示：“Alpheus的声动力疗法代表了一种新颖的、非侵入性的全脑治疗方法，并且有令人信服的早期数据。这项投资反映了我们致力于推进旨在填补患者未满足需求的关键空白的变革性技术。”

Alpheus' platform delivers non-thermal, tumor-selective therapy activated by low-intensity diffuse ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA). Without the need for imaging or sedation, this combination selectively targets and destroys cancer cells across the entire brain hemisphere. This novel treatment option is performed in an outpatient setting.

阿尔菲乌斯平台提供非热、肿瘤选择性治疗，通过低强度扩散超声波（LIDU™）与口服5-氨基乙酰丙酸（5-ALA）激活。无需影像或镇静，这种组合选择性地靶向并摧毁整个大脑半球的癌细胞。这种新颖的治疗方案在门诊环境中进行。

Promising early results from two studies highlight the potential of SDT therapy in both .

两项研究的早期结果令人鼓舞，突显了SDT疗法在两方面的潜力。

newly diagnosed

新诊断的

and

和

recurrent

反复的

glioblastoma patients.

胶质母细胞瘤患者。

'This investment is a key inflection point for Alpheus and the glioblastoma community – advancing sonodynamic therapy from promise to clinical validation,' commented

“这项投资是阿尔菲厄斯和胶质母细胞瘤社区的关键转折点——将声动力疗法从希望推进到临床验证，”评论道。

Vijay Agarwal

维杰·阿加瓦尔

, MD, FAANS, FCNS, President and CEO of Alpheus Medical. 'With this support, we are poised to generate pivotal evidence that could help establish a new standard of care for newly diagnosed brain tumors.'

医学博士，FAANS，FCNS，Alpheus Medical公司总裁兼首席执行官。“有了这一支持，我们准备生成关键证据，这可能有助于为新诊断的脑肿瘤建立新的治疗标准。”

About Alpheus Medical, Inc.

关于阿尔菲斯医疗公司

Alpheus Medical is a private, clinical-stage oncology company developing a groundbreaking, non-invasive treatment for solid tumors utilizing sonodynamic therapy (SDT). Its proprietary platform combines Low-Intensity Diffuse Ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA), a sensitizing agent that selectively accumulates in tumor cells.

Alpheus Medical是一家私人临床阶段的肿瘤学公司，致力于开发一种利用声动力疗法（SDT）的突破性非侵入性实体瘤治疗方法。其专有平台结合了低强度扩散超声波（LIDU™）与口服5-氨基乙酰丙酸（5-ALA），这是一种能够选择性积聚在肿瘤细胞中的增敏剂。

This targeted approach aims to destroy cancer cells while sparing healthy tissue. Alpheus collaborates with global leaders in neuro-oncology and is supported by top healthcare investors and the venture vehicles of nonprofit organizations focused on cancer. Learn more at .

这种有针对性的方法旨在摧毁癌细胞，同时保留健康组织。Alpheus与神经肿瘤学领域的全球领导者合作，并得到顶级医疗保健投资者和专注于癌症的非营利组织的风险投资机构的支持。欲了解更多信息，请访问。

www.alpheusmedical.com

。

About HealthQuest Capital

关于HealthQuest资本

HealthQuest Capital is a private asset firm that provides capital to transformative healthcare companies. HealthQuest Capital focuses on commercial prospects that drive enhanced patient outcomes and elevate the efficiency of healthcare delivery. With approximately

HealthQuest Capital是一家私人资产公司，为变革性的医疗保健公司提供资金。HealthQuest Capital专注于推动患者治疗效果提升和提高医疗交付效率的商业前景。拥有大约

$2 billion

20亿美元

in capital under management, the firm focuses on fostering innovation across the healthcare spectrum, including medical technologies, diagnostics, digital health, and innovative services. The HealthQuest Capital team combines decades of investing experience with domain expertise in the various aspects of the healthcare industry.

管理资本金时，该公司注重促进整个医疗保健领域的创新，包括医疗技术、诊断、数字健康和创新服务。HealthQuest Capital 团队结合了数十年的投资经验和在医疗行业各个方面的领域专业知识。

For more information, visit .

欲了解更多信息，请访问。

www.healthquestcapital.com

。

About Samsara BioCapital

关于Samsara BioCapital

Founded in 2017, Samsara BioCapital is a leading biotech investment firm focused on identifying opportunities across public and private markets. Samsara invests across the full spectrum from early-stage start-up to late-stage clinical assets with a focus on companies that will have a significant impact on patients and address high unmet medical needs.

Samsara BioCapital 成立于2017年，是一家领先的生物技术投资公司，专注于在公开和私人市场中寻找机会。Samsara的投资范围涵盖从早期初创公司到晚期临床资产的整个领域，重点关注那些将对患者产生重大影响并满足高度未满足医疗需求的公司。

Samsara works with entrepreneurs and top-tier management teams that they believe will have a meaningful impact on innovative therapeutics. The Samsara team has deep expertise in biotech with significant experience working together prior to founding the firm. The team is led by .

Samsara与他们认为将对创新治疗产生重大影响的企业家和顶级管理团队合作。Samsara团队在生物技术领域拥有深厚的专业知识，在创立公司之前已有丰富的合作经验。该团队由领导。

Srinivas Akkaraju

斯里尼瓦斯·阿卡拉朱

, who has over twenty-two years of industry experience and has an MD and a PhD in Immunology from

，拥有超过二十二年的行业经验，并且拥有免疫学的医学博士和哲学博士学位，毕业于

Stanford University

斯坦福大学

。

Media Contact

媒体联系人

Carla Benigni

卡拉·贝尼尼